Alpha¹ by KaimenConfidential

Kaimen Rigor review

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.

Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS, VESALIUS-CV Investigators

DOI: 10.1001/jama.2026.3277
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/c70f1914-21c9-4d7e-9084-004be5b64d78 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

Incomplete run — read this verdict with care

Only 2 of 3 reviewers completed. Each verdict below is the majority of 2, not of 3 — the disagreement between reviewers that normally filters out one model's noise could not be applied.
This run hit its time budget: at least one step billed work that never produced a result.

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
92.7% does not match the reported count 1672/1806
“White 1672 (92.7)”
Table 1
02Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The results support lower LDL-C targets in high-risk primary prevention.
supporting lower LDL-C goals in high-risk primary prevention and making a case for a single LDL-C target for all high-risk individuals
Discussionreviewer’s wording

Findings by category

201ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps · partly checked 05AvailabilityNone found · partly checked 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted prespecified subgroup analysis of a randomized controlled trial, with rigorous design, clear reporting, and appropriate statistical methods. The main weakness is the vague data availability statement, which limits reproducibility. Minor copyedit issues and a slightly overstated claim about LDL-C targets are also noted.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal housing, cell line authentication) and were excluded. The statistics verification checked only a subset of tests (4 reported), and the one inconsistent result was not specified; this does not affect the pass status. The claim audit flagged one overstated claim.

Numerical inconsistencies

2 findings · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks. 1 printed percentage that does not match its own count.

Numeric forensics— values impossible for the reported sample size

PERCENT
92.7% does not match the reported count 1672/1806
“White 1672 (92.7)”
Table 1

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p = .009 · recomputed p = .009Reviewers 1, 2
P-value for 3-P MACE hazard ratio from CI
“HR, 0.69 [95% CI, 0.52-0.91]; P = .009”
Taken as given: The hazard ratio is 0.69 with 95% CI 0.52-0.91.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed two-tailed p from HR and 95% CI using normal approximation on log scale.
How we recomputed it: pCI(0.69, 0.52, 0.91, 1)
CONSISTENTreported p = .001 · recomputed p = .001Reviewers 1, 2
P-value for 4-P MACE hazard ratio from CI
“HR, 0.69 [95% CI, 0.55-0.86]; P = .001”
Taken as given: The hazard ratio is 0.69 with 95% CI 0.55-0.86.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed two-tailed p from HR and 95% CI using normal approximation on log scale.
How we recomputed it: pCI(0.69, 0.55, 0.86, 1)
CONSISTENTreported p = .020 · recomputed p = .015Reviewer 1
P-value for all-cause death hazard ratio from CI
“HR, 0.76 [95% CI, 0.61-0.95]”
Taken as given: The hazard ratio is 0.76 with 95% CI 0.61-0.95.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed two-tailed p from HR and 95% CI using normal approximation on log scale.
How we recomputed it: pCI(0.76, 0.61, 0.95, 1)

lowinternal contradiction
The abstract reports 3-P MACE event counts as 83 vs 117, but the forest plot (Figure 3) shows 83 (4.5%) vs 117 (6.5%). The percentages are consistent with the counts (83/1849=4.49%, 117/1806=6.48%). No contradiction.
“A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group”
Figure 3

Overstated conclusions

1 finding · worst medium

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed

9 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

overstatedReviewer 1
The results support lower LDL-C targets in high-risk primary prevention.
The study shows benefit of evolocumab, but the claim about lowering LDL-C targets is an inference beyond the direct evidence, as the trial did not compare different targets.
Evidence: Achieved LDL-C levels of 44 mg/dL at 96 weeks and event reduction
supporting lower LDL-C goals in high-risk primary prevention and making a case for a single LDL-C target for all high-risk individuals
Discussionreviewer’s wording
supportedReviewer 1
Evolocumab reduced the risk of a first major cardiovascular event in patients without known significant atherosclerosis and with diabetes.
The primary endpoint (3-P MACE) showed a significant reduction (HR 0.69, 95% CI 0.52-0.91, P=0.009), directly supporting the claim.
Evidence: 3-P MACE HR 0.69 (95% CI 0.52-0.91), P=0.009
“evolocumab reduced the risk of a first major cardiovascular event.”
Abstract
supportedReviewer 1
The benefit was consistent across secondary endpoints.
Multiple secondary endpoints showed significant reductions with HRs around 0.66-0.69, supporting consistency.
Evidence: Secondary endpoints: MI/ischemic stroke/IDR HR 0.66, CHD death/MI/IDR HR 0.69, CV death/MI/ischemic stroke HR 0.68
evolocumab demonstrated consistent benefit compared with placebo across the prespecified secondary end points within the testing hierarchy
Resultsreviewer’s wording
supportedReviewer 1
The effect of evolocumab was more apparent after the first year.
Landmark analysis showed larger reductions after 1 year (HR 0.59 and 0.61), supporting the claim.
Evidence: Landmark analysis: 41% reduction in 3-P MACE (HR 0.59) and 39% in 4-P MACE (HR 0.61) after 1 year
the effect of evolocumab was more apparent after the first year of treatment
Resultsreviewer’s wording
supportedReviewer 1
The benefit is consistent with the CTTC meta-regression prediction.
Observed HRs of 0.69 and 0.63 for major coronary and vascular events closely match predicted HRs of 0.69 and 0.71, supporting consistency.
Evidence: CTTC end points: HR 0.69 and 0.63 vs predicted 0.69 and 0.71
“the CTTC meta-regression analysis would predict HRs of 0.69 and 0.71, respectively.”
Results
supportedReviewer 2
Evolocumab reduced the risk of a first major cardiovascular event in high-risk patients without known significant atherosclerosis and with diabetes.
The claim is directly supported by the primary endpoint results (3-P MACE HR 0.69, 95% CI 0.52-0.91, P=0.009; 4-P MACE HR 0.69, 95% CI 0.55-0.86, P=0.001).
Evidence: 3-P MACE and 4-P MACE results with HR, 95% CI, and p-values.
“In high-risk patients without known significant atherosclerosis and with diabetes, evolocumab reduced the risk of a first major cardiovascular event.”
Abstract
supportedReviewer 2
The benefit of evolocumab was consistent across subgroups (age, sex, baseline LDL-C).
The paper reports that results were consistent in patients younger and older than 65 years, males and females, and across LDL-C levels, with a forest plot (eFigure 6) supporting this.
Evidence: eFigure 6 in Supplement 4 and text stating consistency.
Results of the primary and secondary end points were consistent in patients younger than and older than 65 years, males and females, and among those with LDL-C levels above and below the median value of 132 mg/dL (eFigure 6 in Supplement 4).
Resultsreviewer’s wording
supportedReviewer 2
The magnitude of cardiovascular benefit was consistent with prior meta-regression analyses for statin therapy.
The paper compares observed HRs for CTTC endpoints with predicted HRs from CTTC meta-regression, showing consistency.
Evidence: eTable 2 and text: observed HRs 0.69 and 0.63 vs predicted 0.69 and 0.71.
On the basis of the between-group difference in the LDL-C level... the CTTC meta-regression analysis would predict HRs of 0.69 and 0.71, respectively.
Resultsreviewer’s wording
supportedReviewer 2
The onset of clinical benefit appeared to differ between patients with and without known atherosclerosis.
The paper describes a landmark analysis and eFigures showing later separation in the no-atherosclerosis group, which is supported by the data presented.
Evidence: Landmark analysis and eFigures 2-4.
The onset of clinical treatment benefit with evolocumab appeared to differ in patients with and without known atherosclerosis.
Discussionreviewer’s wording

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

ADEQUATESurrogate endpoint
The primary efficacy claim is based on hard clinical outcomes (3-P MACE and 4-P MACE composites including death, myocardial infarction, stroke, and revascularization), not a surrogate. The LDL-C reduction is a secondary measure and is not the basis for the efficacy claim.
“A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group (hazard ratio [HR], 0.69 [95% CI, 0.52-0.91]; P = .009; between-group difference, 2.1% [95% CI, 0.4%-3.8%]).”
ADEQUATEEffect size
The effect size is reported as a 31% relative risk reduction in 3-P MACE (HR 0.69) and a 2.1% absolute risk reduction at 5 years, which is clinically meaningful in a primary prevention population. The effect is statistically significant and anchored to clinical outcomes.
“A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group (hazard ratio [HR], 0.69 [95% CI, 0.52-0.91]; P = .009; between-group difference, 2.1% [95% CI, 0.4%-3.8%]).”

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior work showing cardiovascular benefit of LDL-C lowering with statins and PCSK9 inhibitors, primarily in secondary prevention. It notes that VESALIUS-CV demonstrated benefit in a lower-risk population but most patients had known significant atherosclerosis. The rationale for this prespecified subgroup analysis is clearly stated: to investigate benefit in patients without known significant atherosclerosis and with diabetes. Limitations of prior work (focus on secondary prevention) are acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior trials and guidelines, and logically justifies the subgroup analysis.

Evidence

paraphrase[Introduction, paragraph 1]

“Over several decades, large randomized clinical trials have demonstrated the cardiovascular benefit of statins, high-intensity statins, and, subsequently, the addition of nonstatin low-density lipoprotein cholesterol (LDL-C)–lowering therapy.”

paraphrase[Introduction, paragraph 2]

“This prespecified subgroup analysis of the VESALIUS-CV trial investigated the potential benefit of early intensive LDL-C lowering with evolocumab among individuals without known significant atherosclerosis and with diabetes.”

paraphrase[Introduction, paragraph 2]

“However, most of the patients in VESALIUS-CV had known significant atherosclerosis, with either prior revascularization, arterial stenoses of 50% or greater, or a coronary artery calcium score ≥100 Agatston units.”

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific premise by citing prior trials (FOURIER, ODYSSEY-OUTCOMES, VESALIUS-CV) and guidelines, and provides a logical rationale for the subgroup analysis.

Evidence

paraphrase[Introduction, paragraph 1]

“However, these trials have predominantly been performed in secondary prevention populations, leading to clinical guidelines recommending more intensive LDL-C–lowering therapy and lower LDL-C targets in patients after a cardiovascular event has already occurred.”

paraphrase[Introduction, paragraph 2]

“However, these trials have predominantly been performed in secondary prevention populations”

Introduction ¶1

Randomization method (block randomization through central computer system) and unit (patient) are reported. Blinding is described as double-blind. Inclusion/exclusion criteria are clearly defined. Power analysis was performed for the overall trial but not for this subgroup, which is acknowledged. Outlier handling is addressed through the intention-to-treat analysis and prespecified analysis populations. Controls are the placebo group. Independent replication is not applicable for a single trial, but the paper notes the need for prospective testing.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, double-blind, placebo-controlled, with adequate randomization, blinding, and prespecified analysis. Power analysis was not performed for this subgroup, but that is acknowledged and acceptable for a subgroup analysis.

Evidence

paraphrase[Methods, Study Design and Population]

“Block randomization through a central computer system was used to randomly assign eligible participants in a 1:1 ratio to receive subcutaneous injections of evolocumab at a dosage of 140 mg every 2 weeks or matching placebo.”

“VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab”

Abstract

“Power calculations were performed for the overall trial but not for this subgroup.”

Statistical analysis

PASSReviewer 2· 95% conf

The parent trial is a well-designed RCT with adequate randomization, blinding, and prespecified subgroup analysis. Most applicable sub-criteria are adequately reported.

Evidence

paraphrase[Methods, Study Design and Population]

“VESALIUS-CV was a randomized, double-blind, placebo-controlled trial”

Methods

“Power calculations were performed for the overall trial but not for this subgroup.”

Statistical analysis

The paper reports age (median 65 years), sex (57% female), race/ethnicity, weight, BMI, geographic region, medical history (diabetes, hypertension, smoking), and baseline lipid levels. These are adequate for a human clinical trial. Species/strain/housing are not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and comorbidities. Sex is reported and both sexes are included, so no justification for single-sex is needed.

Evidence

“The median age of patients was 65 years (IQR, 60-70), and 57% were female.”

Results

“White 1711 (92.5) 1672 (92.7)”

Table 1

“Diabetes c 1845 (99.8) 1805 (99.9)”

Table 1

PASSReviewer 2· 95% conf

Demographics, age, sex, and key clinical characteristics are well reported. Species/strain/housing are not applicable for a human trial.

Evidence

“Sex, No. (%) Female 1042 (56.4) 1024 (56.7) Male 807 (43.6) 782 (43.3)”

Table 1

“The median age of patients was 65 years (IQR, 60-70)”

Results

“Race, No. (%) a Asian 37 (2.0) 34 (1.9) Black 61 (3.3) 66 (3.7) White 1711 (92.5) 1672 (92.7)”

Table 1

The paper states that the protocol was approved by ethics committees at participating sites and that all patients provided written informed consent. This satisfies both irb_ethics_statement and informed_consent. Regulatory compliance is indicated by the mention of Good Clinical Practice violations in the figure footnote, implying adherence to ICH-GCP. The trial is registered (NCT03872401).

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are clearly reported, and regulatory compliance is implied through adherence to Good Clinical Practice.

Evidence

paraphrase[Methods, Trial Organization and Oversight]

“The protocol was approved by ethics committees at participating sites, and all patients provided written informed consent before enrollment.”

“Does not include 44 individuals excluded from all analyses due to a site-wide serious breach and Good Clinical Practice violations.”

Figure 1

PASSReviewer 2· 95% conf

Ethics approval and informed consent are adequately reported. The trial is registered.

Evidence

paraphrase[Methods, Trial Organization and Oversight]

“The protocol was approved by ethics committees at participating sites, and all patients provided written informed consent before enrollment.”

“ClinicalTrials.gov Identifier: NCT03872401”

Abstract

Evolocumab is named with manufacturer (Amgen) and dose/regimen (140 mg every 2 weeks). The placebo is described as matching. Statistical software (SAS version 9.4) is identified. Antibodies, cell lines, mycoplasma, and organisms are not applicable. Reagents are limited to the investigational product, which is adequately described.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (evolocumab) is adequately identified with dose and regimen, and statistical software is identified. No other biological/chemical resources are applicable.

Evidence

paraphrase[Methods, Study Design and Population]

“receive subcutaneous injections of evolocumab at a dosage of 140 mg every 2 weeks or matching placebo.”

“Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc).”

Statistical analysis

PASSReviewer 2· 90% conf

The investigational product (evolocumab) and comparator (placebo) are identified with dose and regimen. Statistical software is identified. No other key biological resources are used.

Evidence

“Patients were randomized in a 1:1 ratio to subcutaneous administration of either evolocumab (140 mg every 2 weeks) or matching placebo”

Abstract

“Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc).”

Statistical analysis

Tests are named (log-rank test, Cox model, mixed model with repeated measures). Assumptions are verified (proportional hazards confirmed via Schoenfeld residuals). Exact p-values are reported (e.g., P = .009). Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes Kaplan-Meier curves and forest plots with per-group n. Mathematical plausibility checks are not applicable for large-N continuous outcomes, but no obvious errors are apparent.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals. The analysis follows clinical trial reporting standards.

Evidence

paraphrase[Methods, Statistical Analysis]

“Time-to-event analyses were performed using the log-rank test, with stratification by baseline LDL-C level and geographic region.”

paraphrase[Methods, Statistical Analysis]

“The proportional hazard assumption was confirmed for each end point after assessment of scaled Schoenfeld residuals on functions of time and tests of whether the association was time-dependent.”

“HR, 0.69 [95% CI, 0.52-0.91]; P = .009”

Results

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, software is identified, and data presentation is adequate. Exact p-values are provided for primary and key secondary endpoints.

Evidence

paraphrase[Methods, Statistical Analysis]

“Time-to-event analyses were performed using the log-rank test, with stratification by baseline LDL-C level and geographic region. In addition, hazard ratios (HRs) with 95% CIs were estimated from a Cox model, stratified as above.”

paraphrase[Methods, Statistical Analysis]

“The proportional hazard assumption was confirmed for each end point after assessment of scaled Schoenfeld residuals on functions of time and tests of whether the association was time-dependent.”

paraphrase[Results, Major Cardiovascular Events]

“A 3-P MACE occurred in 83 patients... (HR, 0.69 [95% CI, 0.52-0.91]; P = .009)”

The paper states: 'The trial database is not publicly available, but interested parties can contact the corresponding author (N.A.M.).' This is a vague statement without a clear mechanism, conditions, or timeframe, making it reported_but_inadequate. No code sharing is mentioned. No repository deposit or accession numbers are provided.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

A data availability statement is present but vague, stating data are available on request from the corresponding author without a clear mechanism or timeframe. No code is shared.

Evidence

paraphrase[Methods, Trial Organization and Oversight]

“The trial database is not publicly available, but interested parties can contact the corresponding author (N.A.M.).”

WARNReviewer 2· 90% conf

A data availability statement is present but vague ('contact the corresponding author'), and no code is shared. The trial database is not publicly available.

Evidence

paraphrase[Methods, Trial Organization and Oversight]

“The trial database is not publicly available, but interested parties can contact the corresponding author (N.A.M.).”

absence[Entire paper]

No code sharing is mentioned.

Trial registration number is provided (NCT03872401). CONSORT reporting is stated. All prespecified outcomes are reported, including secondary and exploratory. Limitations are explicitly discussed. Conclusions are proportional to the evidence, acknowledging the subgroup nature. Funding and conflicts of interest are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper is transparent: trial registration, CONSORT reporting, limitations, and funding/COI are all reported. All outcomes are reported, and conclusions are proportional.

Evidence

“ClinicalTrials.gov Identifier: NCT03872401”

Abstract

“Reporting of this trial follows the CONSORT reporting guidelines.”

Statistical analysis

paraphrase[Discussion, Limitations]

“First, imaging to assess atherosclerosis was not performed in all patients; thus, it is possible that some may have had undiagnosed significant atherosclerosis.”

PASSReviewer 2· 95% conf

The paper is well-structured, follows CONSORT guidelines, discusses limitations, and provides proportional conclusions. Trial registration and funding/COI are reported.

Evidence

“ClinicalTrials.gov Identifier: NCT03872401”

Abstract

“Reporting of this trial follows the CONSORT reporting guidelines.”

Statistical analysis

paraphrase[Discussion, Limitations]

“This study has several potential limitations. First, imaging to assess atherosclerosis was not performed in all patients...”

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

ClinicalTrials.gov

NCT03872401

Reporting guidelines: CONSORT

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 16 references by DOI: 16 verified.

Every extracted reference resolved against Crossref/OpenAlex with no retraction flags.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

MINORtypoAbstract, Results
“P < .001”
→ P < .001
Spacing in p-value is inconsistent; elsewhere it is 'P = .009'.
MINORconsistencyFigure 1 footnote
“No exclusion logs were maintained to determine the number of people evaluated for the trial.”
→ Consider moving this to Methods for clarity.
This statement is important but placed in a figure footnote.
MINORconsistencyTable 1 footnote
“SI conversion factors: To convert LDL-C, HDL-C, and non–HDL-C values to mmol/L, multiply by 0.0259; triglycerides values to mmol/L, multiply by 0.0113; apolipoprotein B values to g/L, multiply by 0.01.”
→ Add 'to' before 'triglycerides values' for parallel structure: 'triglycerides values to mmol/L' -> 'triglyceride values to mmol/L'.
Minor grammatical inconsistency.
MINORclarityMethods, Statistical Analysis
“Power calculations were performed for the overall trial but not for this subgroup.”
→ Consider adding a brief justification for why subgroup power was not calculated (e.g., 'as is typical for prespecified subgroup analyses').
Clarity improvement.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported, with only minor reporting gaps. An informed reader should weigh the vague data availability statement and the lack of code sharing, which limit independent verification. The overstated claim about LDL-C targets should be tempered in any correction or re-analysis.

1.
HIGHdata code
Replace the vague data availability statement in the Methods (Trial Organization and Oversight) with a concrete managed-access mechanism, e.g., 'Data are available through a data-sharing agreement with the TIMI Study Group; requests should be submitted to the corresponding author and will be reviewed within 30 days.'
The current 'contact the corresponding author' statement lacks a clear mechanism, conditions, or timeframe, which is inadequate for reproducibility.
2.
HIGHdata code
Add a code sharing statement in the Data Sharing Statement (Supplement 6) indicating whether custom analysis code is available and, if so, where (e.g., GitHub, Zenodo with DOI).
No code sharing is mentioned, which limits the ability of others to reproduce the analyses.
3.
HIGHreporting
Temper the claim in the Discussion that 'the results support lower LDL-C targets in high-risk primary prevention' to reflect that the trial did not compare different LDL-C targets directly.
The claim audit rated this as overstated; the study shows benefit of evolocumab but does not directly test target levels.
4.
MEDIUMreporting
Add a brief justification in the Methods (Statistical Analysis) for why power calculations were not performed for this subgroup, e.g., 'as is typical for prespecified subgroup analyses.'
Clarifies the absence of subgroup power analysis and preempts reader questions.
5.
MEDIUMreporting
Report the number of patients with missing data for key variables and how missing data were handled in the Statistical Analysis section.
A general missing data statement is absent, which is important for transparency in a clinical trial.
6.
MEDIUMreporting
Move the statement 'No exclusion logs were maintained to determine the number of people evaluated for the trial' from the Figure 1 footnote to the Methods section.
This important methodological limitation is currently buried in a figure footnote.
7.
LOWcopyedit
Standardize p-value formatting in the Abstract (e.g., use 'P < .001' consistently with 'P = .009' elsewhere).
Inconsistent spacing in p-values is a minor copyedit issue.
8.
LOWcopyedit
Fix the grammatical inconsistency in Table 1 footnote: change 'triglycerides values to mmol/L' to 'triglyceride values to mmol/L'.
Minor grammatical error in the SI conversion factors.

Full text (44,371 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.

DOI

10.1001/jama.2026.3277

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20